Back to Explorer

CVM GFI #262 Pre-Submission Consultation Process for Animal Food Additive Petitions or Generally Recognized as Safe (GRAS) Notices

FinalCenter for Veterinary Medicine12/11/2020

Description

This guidance describes the types of information the Food and Drug Administration’s (FDA’s) Center for Veterinary Medicine (CVM) recommends be included in:

Scope & Applicability

Product Classes

1
Animal Food Additive

Substances added to animal food requiring approval

Stakeholders

7
Petitioner

Party submitting a citizen petition; party evaluating whether a food allergen is of public health importance; Party recommended to conduct systematic reviews and evidence scoring.

Study personnel

treatment blinding to study personnel

Study sponsor

Entity that authorizes protocol deviations in writing.

Sponsor

Entity responsible for submitting applications under section 524B

Investigator

Responsible for qualifications, training, and trial conduct; Individual responsible for trial conduct and data governance at a site.; May delegate tasks but retains overall responsibility; Person responsible for the conduct of the clinical trial at a trial site; Responsible for trial conduct and participant safety; Responsible for trial conduct, data integrity, and investigational product management.; Individual responsible for trial conduct at a site and informing the institution.; maintaining

Notifier

The manufacturer or distributor submitting the notification; The person or firm submitting the NDIN

Qualified Experts

Required for GRAS status determinations

Regulatory Context

Attributes

6
Pivotal Data

Data providing the primary basis for a safety conclusion

Power of the study

number of animals used in the study should be justified in terms of the power of the study

Level of significance

Information such as hypotheses tested, parameters estimated, assumptions made, level of significance

Nutritional requirements

Requirements of study animals that must be met during the study.

Target Animal Safety

Data requested by CVM to demonstrate the safety of the cat food

Withdrawal period

Time required before slaughter to ensure no residues; time animals must be held after drug treatment before slaughter

Identified Hazards

Hazards

3
Carcinogenicity

risk assessment for pharmaceuticals affecting the immune system

Extraordinary circumstances

circumstances indicating potential for serious harm to the environment

Toxicity

Assessment of toxicity required in a 351(k) BLA

Related CFR Sections (10)

Related Warning Letters (9)

  • Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies

    CCIC Huatongwei International Inspection Co., Ltd.

    2025-08-26
  • Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies

    Jiangsu Kerbio Medical Technology Group Co.

    2025-08-26
  • Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)

    Mid-Link Testing Company, Ltd

    2024-09-11
  • Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)

    Sanitation & Environmental Technology Institute dba SDWH

    2024-09-11
  • Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies

    Samm Solutions, Inc., d.b.a. BTS Research

    2023-10-31
  • Bioresearch Monitoring Program

    Valley Biosystems

    2022-08-09
  • Good Laboratory Practice (GLP)

    Toxikon Corporation/Labcorp Bedford LLC

    2022-02-22
  • Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies

    University of Kentucky

    2020-05-05
  • Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies

    Steiner Biotechnology, LLC

    2020-04-07

See Also (8)